Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Royalty Pharma Q2 Adj $0.96 Misses $0.99 Estimate, Sales $537.00M Miss $628.26M Estimate

Author: Benzinga Newsdesk | August 08, 2024 07:03am
Royalty Pharma (NASDAQ:RPRX) reported quarterly earnings of $0.96 per share which missed the analyst consensus estimate of $0.99 by 3.03 percent. This is a 14.29 percent increase over earnings of $0.84 per share from the same period last year. The company reported quarterly sales of $537.00 million which missed the analyst consensus estimate of $628.26 million by 14.53 percent. This is a 0.19 percent decrease over sales of $538.00 million the same period last year.

Posted In: RPRX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist